Matrixyl

Matrixyl is the proprietary trade name (Sederma, France) for palmitoyl pentapeptide-4, a lipidated cosmetic peptide consisting of the pentapeptide sequence Lys-Thr-Thr-Lys-Ser (KTTKS) covalently conjugated at its N-terminus to a palmitic-acid (C16:0) fatty acid. The unmodified KTTKS sequence is a fragment of the C-terminal propeptide of type I procollagen — a portion of the procollagen precursor that is cleaved during procollagen maturation and that has been characterized in dermal-fibroblast research as a feedback signal regulating collagen production. Sederma's lipidation of KTTKS with a palmitic-acid tail produced palmitoyl pentapeptide-4 (Matrixyl), a molecule with substantially improved skin penetration compared to the unmodified hydrophilic pentapeptide.

The Matrixyl product was introduced in the late 1990s and became one of the foundational examples of the "cosmeceutical peptide" category — short peptides incorporated into topical skincare formulations on the rationale of supporting dermal extracellular matrix biology. The published dermal-fibroblast research on Matrixyl and the parent KTTKS sequence has investigated effects on collagen I, collagen III, fibronectin, and glycosaminoglycan synthesis in cultured fibroblasts and skin-explant models. The molecule and its successors (Matrixyl 3000, a combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7; Matrixyl Synthe'6, palmitoyl tripeptide-38) are widely used as active ingredients in topical anti-aging skincare formulations.

This page is a research-only educational reference for Matrixyl as a research peptide. The molecule is not a medicine; it is a cosmetic-ingredient peptide used in topical formulations. Research-supply Matrixyl is intended for laboratory and analytical work and for formulation development. No medical or therapeutic claims are made on this page.

Matrixyl is palmitoyl pentapeptide-4 (INCI name: Palmitoyl Pentapeptide-4). The structure is N-palmitoyl-Lys-Thr-Thr-Lys-Ser, with the palmitic-acid C16 fatty acid amide-linked to the N-terminal α-amine of the lysine. The molecular weight is approximately 802.1 g/mol. The product is sometimes referred to in the cosmetic-ingredient literature by the earlier name "palmitoyl pentapeptide-3" (an outdated INCI designation for the same molecule before re-numbering of the palmitoyl-pentapeptide series).

The unmodified KTTKS pentapeptide sequence is derived from the C-terminal propeptide region of type I procollagen. In normal procollagen biology, type I procollagen is secreted by dermal fibroblasts as a precursor with N-terminal and C-terminal propeptide extensions. After secretion, specific proteases (BMP-1 for the C-propeptide, ADAMTS for the N-propeptide) cleave these propeptides to release the mature tropocollagen monomer that assembles into collagen fibrils. The released C-propeptide has been characterized as a feedback signal regulating fibroblast collagen production — a "PICP" (procollagen I C-terminal propeptide) circulating biomarker is used clinically in bone and connective-tissue research as a marker of collagen synthesis rate. The KTTKS sequence corresponds to a specific portion of this released C-propeptide.

The functional rationale for the palmitoyl modification is improved skin penetration. The unmodified KTTKS pentapeptide is hydrophilic and penetrates the stratum corneum poorly, limiting its topical bioavailability. The palmitic-acid tail provides the molecule with amphipathic character — a hydrophilic peptide head and a hydrophobic lipid tail — that allows it to partition into the stratum corneum lipid lamellae and to be delivered more effectively into the viable epidermis and dermis where fibroblasts reside. The lipidation approach is widely used in cosmetic peptide chemistry, and palmitoyl- and myristoyl-modified derivatives are common across the cosmeceutical-peptide product category.

The biological activity of Matrixyl in published dermal-fibroblast research includes stimulation of collagen I, collagen III, fibronectin, and glycosaminoglycan synthesis at low concentrations (nanomolar to low micromolar range). The mechanism is incompletely characterized; the parent KTTKS sequence is hypothesized to act as a feedback agonist of the procollagen-C-propeptide regulatory signaling, but the receptor target and downstream signaling pathway are not definitively established. Published clinical-research studies on topical Matrixyl-containing formulations in human skin have reported improvements in wrinkle measurements and skin-texture parameters across various study durations and formulations.

It is important to be clear about what Matrixyl is not. It is not a medicine — it is a cosmetic ingredient used in topical skincare formulations. It is not a "growth factor" in the cytokine sense — it is a small synthetic peptide. And the cosmeceutical claims associated with topical Matrixyl-containing products should be understood within the regulatory framework for cosmetics, which permits structure/function claims about cosmetic effects on appearance but does not extend to therapeutic claims.

The recognition that procollagen propeptides function as feedback signals regulating fibroblast collagen production emerged from procollagen-biology research in the 1980s and 1990s. Several research groups characterized the C-propeptide of type I procollagen as a regulator of collagen mRNA expression and protein synthesis in dermal fibroblast cultures. The KTTKS sequence within the C-propeptide was identified as a region that retained biological activity when synthesized as a free pentapeptide, suggesting potential utility in topical formulations designed to support dermal collagen synthesis.

Sederma, a French specialty cosmetic-ingredients company (part of the Croda International group), developed Matrixyl as a lipidated derivative of the KTTKS pentapeptide in the late 1990s. The palmitic-acid modification was chosen to address the poor stratum corneum penetration of the unmodified hydrophilic peptide. Matrixyl was launched commercially in 2000 and became one of the foundational examples of the cosmeceutical peptide category. The product attracted substantial attention in cosmetic-ingredient research and in the broader cosmetic industry as an example of evidence-supported topical peptide chemistry.

The successor products Matrixyl 3000 and Matrixyl Synthe'6 were developed in subsequent years. Matrixyl 3000 is a combination of palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR), introduced in 2003. The GHK tripeptide is itself a well-characterized biologically active sequence (the glycyl-histidyl-lysine peptide that, in its native form and as the GHK-copper(II) complex, has been studied extensively in wound-healing and skin-biology contexts since the 1970s work of Pickart and colleagues). Matrixyl Synthe'6 is palmitoyl tripeptide-38, introduced in 2010 with a focus on stimulating six matrix proteins beyond collagen I and III.

The Matrixyl family is widely distributed in topical skincare formulations from many cosmetic manufacturers and remains a recognized active-ingredient category. The molecules have been studied in published cosmetic-research literature for fibroblast effects, topical-delivery characterization, and clinical-research evaluation of formulated products in human skin. The cosmeceutical-peptide literature has both passionate supporters and substantive critics; the appropriate framing is that the published research supports certain in-vitro and clinical-research findings while the magnitude of in-vivo topical effects in real-world cosmetic use remains an active area of evaluation.

Matrixyl and its successors are not approved as medicines and are not subject to pharmaceutical regulatory approval; they are cosmetic ingredients regulated under the cosmetic-product framework of the FDA in the US, the Cosmetics Regulation in the EU, and equivalent frameworks in other jurisdictions.

Type I collagen is the dominant collagen of the dermal extracellular matrix and is produced by dermal fibroblasts as type I procollagen — a precursor with N-terminal and C-terminal propeptide extensions that flank the central triple-helical region. After secretion, the N-propeptide is cleaved by ADAMTS-family proteases (notably ADAMTS-2) and the C-propeptide is cleaved by bone morphogenetic protein-1 (BMP-1, also called procollagen C-proteinase). The released mature tropocollagen monomer assembles into collagen fibrils with covalent cross-links provided by lysyl oxidase. This is the canonical pathway by which dermal collagen architecture is established and maintained.

The released propeptides have additional biological roles beyond serving as solubility-promoting precursors. The N-propeptide and C-propeptide of type I procollagen circulate in plasma at measurable concentrations (PINP and PICP, respectively) and are used as biomarkers of bone and connective-tissue collagen synthesis. The C-propeptide has been characterized as a feedback regulator of fibroblast collagen production — accumulation of the released C-propeptide signals back to fibroblasts and modulates further collagen synthesis. The KTTKS sequence within the C-propeptide is the basis for the Matrixyl design.

In cultured dermal fibroblast studies, KTTKS and palmitoyl-KTTKS (Matrixyl) stimulate collagen I, collagen III, fibronectin, and glycosaminoglycan synthesis at low concentrations. The receptor target and downstream signaling pathway are not definitively established in the published literature. Proposed mechanisms include direct interaction with fibroblast cell-surface receptors of unknown identity, modulation of TGF-β signaling, and effects on collagen gene transcription through pathways downstream of the procollagen-C-propeptide feedback loop. The mechanistic uncertainty is one of the characteristic features of cosmeceutical-peptide pharmacology in published research.

The topical-delivery characterization of Matrixyl involves penetration studies in excised human skin (in-vitro Franz-cell diffusion studies), in animal skin models, and in human in-vivo formulation studies. The palmitic-acid modification provides amphipathic character that supports stratum corneum partition and delivery into viable epidermis and dermis. The kinetics of topical delivery, the equilibrium tissue concentrations achieved, and the persistence of effect after discontinuation of topical application are all relevant pharmacological parameters that have been characterized in published cosmeceutical-research literature.

Clinical-research studies of topical Matrixyl-containing formulations in human skin have reported wrinkle-depth reductions, improvements in skin-texture measurements, and improvements in subjective skin-appearance assessments across various study durations. The effect magnitudes are modest in the context of cosmetic-product evaluation; the appropriate framing is that the molecule contributes to a cosmetic-product effect rather than producing a transformative dermal change.

The broader cosmeceutical-peptide landscape includes Matrixyl and its successors alongside palmitoyl tripeptide-1 (GHK-Cu's lipidated analog), Argireline (acetyl hexapeptide-8 / acetyl hexapeptide-3, a SNAP-25 fragment with neuromuscular focus), copper peptides (GHK-Cu, AHK-Cu), and various other peptide-active cosmetic ingredients. Each occupies a different mechanistic and product-positioning niche within the topical anti-aging skincare category.

Matrixyl (palmitoyl pentapeptide-4) is the N-palmitoyl conjugate of the pentapeptide Lys-Thr-Thr-Lys-Ser (KTTKS). The palmitic-acid (C16:0 saturated fatty acid) is amide-linked to the N-terminal α-amine of the lysine residue. The molecular weight is approximately 802.1 g/mol. The molecule is amphipathic — a hydrophilic pentapeptide head with multiple hydroxyl (threonine, serine) and basic (lysine) functional groups, and a hydrophobic palmitic-acid tail.

The unmodified KTTKS pentapeptide is derived from the C-terminal propeptide region of type I procollagen. The choice of palmitic acid (C16:0) for the lipidation is consistent with the general approach in lipidated cosmetic peptide chemistry; palmitic-, myristic-, and stearic-acid modifications are common across the category and provide different balance points between stratum corneum partition and aqueous solubility.

Research-grade Matrixyl is produced by solid-phase peptide synthesis followed by N-terminal palmitoyl conjugation, purified by reversed-phase HPLC to ≥98% purity, and verified by analytical HPLC and mass spectrometry. The molecule is supplied as a lyophilized powder or, more commonly in the cosmetic-formulation context, as a solution in propylene glycol, glycerol, or another cosmetic-compatible solvent at a standardized concentration (typically 100 ppm or 500 ppm of palmitoyl pentapeptide-4 in the supplied solution). Storage is at refrigerated temperature; the lipidated peptide has good solution stability under appropriate formulation conditions.

In published cosmetic and dermal-fibroblast research, Matrixyl has been used in several principal applications:

Cultured fibroblast assays. Primary human dermal fibroblasts and immortalized fibroblast cell lines are treated with KTTKS or Matrixyl at low concentrations to investigate collagen I, collagen III, fibronectin, and glycosaminoglycan synthesis. The published in-vitro literature provides the principal mechanistic evidence base for the molecule.

Topical-delivery characterization. Excised human skin in Franz-cell diffusion assays, animal-skin models, and human in-vivo formulation studies are used to characterize the percutaneous penetration of Matrixyl and to compare formulations for delivery efficiency. The palmitic-acid modification's role in stratum corneum partition is the principal focus.

Clinical-research evaluation of topical formulations. Topical Matrixyl-containing cosmetic formulations have been evaluated in published clinical-research studies in human skin for effects on wrinkle measurements (typically by replica/profilometry methods), skin-texture parameters, hydration, and subjective appearance. Studies typically span 4-12 weeks of twice-daily topical application.

Skin-explant models. Ex-vivo human skin explants are used to investigate Matrixyl effects on collagen synthesis and extracellular matrix biology in a system that retains tissue architecture and the cellular composition of human skin.

Comparative cosmeceutical-peptide research. Matrixyl is studied alongside Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7), Matrixyl Synthe'6 (palmitoyl tripeptide-38), GHK-Cu and other copper peptides, Argireline, and various other cosmeceutical-active peptides in comparative cosmetic-ingredient research and formulation development.

Cosmetic formulation development. Beyond academic research, Matrixyl is widely used as an active ingredient in topical skincare formulations from many cosmetic manufacturers. Research-supply Matrixyl supports formulation development for new cosmetic products in this category.

All applications in the research-supply context are research- and formulation-development context. Nothing on this page describes a clinical protocol or medical-research therapy.

Matrixyl sits within the cosmeceutical-peptide active-ingredient category alongside successor products and other peptide-active cosmetic ingredients.

Matrixyl is the Sederma trade name for palmitoyl pentapeptide-4, a lipidated cosmetic peptide consisting of the pentapeptide KTTKS (a fragment of the C-terminal propeptide of type I procollagen) conjugated at its N-terminus to a palmitic-acid (C16) fatty acid. Introduced in 2000, the molecule became one of the foundational examples of the cosmeceutical peptide category and remains a widely used active ingredient in topical anti-aging skincare formulations. The palmitic-acid modification provides amphipathic character for stratum corneum partition and delivery into viable epidermis and dermis where fibroblasts reside.

In published research, Matrixyl stimulates collagen I, collagen III, fibronectin, and glycosaminoglycan synthesis in cultured dermal fibroblasts at low concentrations, with a hypothesized mechanism involving modulation of the procollagen-C-propeptide feedback loop. Topical clinical-research studies have reported wrinkle-depth reductions and skin-texture improvements in human skin. The molecule is a cosmetic ingredient, not a medicine; successor products in the same Sederma family include Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) and Matrixyl Synthe'6 (palmitoyl tripeptide-38).

This page is research educational only. Matrixyl supplied as a research-supply or formulation-development ingredient is intended for laboratory and analytical work; no medical or therapeutic claims are made.